Recruiting PHASE2 INTERVENTIONAL 10-arm NCT05633667

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Sponsor: Arcus Biosciences, Inc.

Conditions Advanced or Metastatic Non-Small-Cell Lung Cancer Lung Cancer Resectable Non-Small-Cell Lung Cancer

Interventions Carboplatin Cisplatin Docetaxel Domvanalimab (DOM) Etrumadenant (ETRUMA) Nab-paclitaxel Nivolumab Paclitaxel Pemetrexed Sacituzumab govitecan-hziy (SG) Zimberelimab (ZIM)

Updated 25 times since 2022 Last updated: Feb 12, 2026 Started: Mar 16, 2023 Primary completion: Sep 30, 2029 Completion: Sep 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced or Metastatic Non-Small-Cell Lung Cancer and Lung Cancer and is currently actively recruiting participants. Arcus Biosciences, Inc. leads this study, which shows 25 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

25 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2

▶ Show 20 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Sep 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2022 — May 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arcus Biosciences, Inc.
Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Atakum, Turkey (Türkiye) , Austin, United States , Barretos, Brazil , Birmingham, United Kingdom , Changhua, Taiwan , Cheongju-si, South Korea , Cincinnati, United States and 29 more locations